文献速递临床试验与 GCP基础与转化研究真实世界研究与卫生经济

基于患者个体化数字精准诊断的脓毒症治疗优化:DigiSep 试验研究方案

Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial.
PubMed 文献 · Trials · 2021-10-18

DigiSep 试验是一项随机、对照、干预性、开放标签、多中心研究,计划纳入 410 例脓毒症/脓毒性休克患者,比较基于二代测序(NGS)的数字精准诊断联合标准微生物学分析与单纯标准微生物学分析的效果。主要终点为 DOOR-RADAR 评分,同时评估成本效益。

要点

  • NGS 联合标准微生物学分析可能改善脓毒症患者的 DOOR-RADAR 综合结局。
  • 研究同时评估该诊断策略的成本效益及对生活质量的影响。
  • 两组均接受额外的抗感染专家会诊。

核心结论

  • 旨在验证基于 NGS 的数字精准诊断联合标准微生物学分析能否改善脓毒症/脓毒性休克患者的 DOOR-RADAR 综合结局。

研究设计与样本

  • 随机、对照、干预性、开放标签、多中心试验,计划纳入 410 例脓毒症/脓毒性休克患者(每组 205 例)。

关键数值与推荐

  • 主要终点为 DOOR-RADAR 评分,包含重症/中间监护病房住院时长、抗生素消耗量、死亡率和急性肾损伤(AKI)。
  • 假设该诊断策略可降低重症/中间监护病房住院时长、死亡率、AKI 发生率、抗微生物治疗时长及并发症与门诊后照护费用,并显著改善患者生活质量。

临床怎么用

  • 若验证有效,基于 NGS 的诊断概念可作为国家标准的组成部分,用于脓毒症的精准抗感染治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures represent a promising alternative. In particular, the plasmatic detection of circulating, cell-free DNA by next-generation sequencing (NGS) has shown to be suitable for identifying disease-causing pathogens in patients with bloodstream infections. METHODS: The DigiSep-Trial is a randomized, controlled, interventional, open-label, multicenter trial characterizing the effect of the combination of NGS-based digital precision diagnostics with standard-of-care microbiological analyses compared to solely standard-of-care microbiological analyses in the clinical picture of sepsis/septic shock. Additional anti-infective expert consultations are provided for both study groups. In 410 patients (n = 205 per arm) with sepsis/septic shock, the study examines whether the so-called DOOR-RADAR (Desirability of Outcome Ranking/Response Adjusted for Duration of Antibiotic Risk) score (representing a combined endpoint including the criteria (1) intensive/intermediate care unit length of stay, (2) consumption of antibiotics, (3) mortality, and (4) acute kidney injury (AKI)) can be improved by an additional NGS-based diagnostic concept. We also aim to investigate the cost-effectiveness of this new diagnostic procedure. It is postulated that intensive/intermediate care unit length of stay, mortality rate, incidence of AKI, the duration of antimicrobial therapy as well as the costs caused by complications and outpatient aftercare can be reduced. Moreover, a significant improvement in patient's quality of life is expected. DISCUSSION: The authors´ previous work suggests that NGS-based diagnostics have a higher specificity and sensitivity compared to standard-of-care microbiological analyses for detecting bloodstream infections. In combination with the here presented DigiSep-Trial, this work provides the optimal basis to establish a new NGS-driven concept as part of the national standard based on the best possible evidence. TRIAL REGISTRATIONS: DRKS-ID DRKS00022782 . Registered on August 25, 2020 ClinicalTrials.gov NCT04571801 . Registered October 1, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brenner T, Skarabis A, Stevens P, et al. Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial. Trials. 2021. PMID: 34663439. doi:10.1186/s13063-021-05667-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。